drug combination
187 articles
PLATINUM Clinical Trial Actively Recruiting
The PLATINUM clinical trial, for patients with BRCA and PALB2 mutations, seeks participants. Dr. Andrew Ko outlines the trial.
Slowing the Growth of One Type of Advanced Neuroendocrine Tumor
Dr. Kelsey Klute explains the advantages of the radiopharmaceutical lutetium Lu 177 dotatate treatment for certain neuroendocrine tumors.
New Research Sheds Light on Hot and Cold Tumors
Dr. Ben Z. Stanger and his team are finding links between the number of T cells a tumor has and the effectiveness of immunotherapy.
PanCAN 2021 Annual Scientific Summit
Pancreatic Cancer Action Network (PanCAN) held its annual scientific summit for an overview of the latest research projects they are funding.
Targeting the Undruggable KRAS Protein
Dr. Shubham Pant is focusing his research on effective treatments for the KRAS mutation, found in 90% of pancreatic cancers.
The Promise of Organoids
Dr. Brian Wolpin explains how organoids are being used to develop personalized treatment for pancreatic cancer patients.
Modifying the Tumor Microenvironment to Make Treatment More Effective
Researchers are testing a new drug that better-allows chemotherapy to penetrate the tumor microenvironment of pancreatic cancer.
Advances in Pancreatic Neuroendocrine Tumor (PNET) Treatments
Dr. Diane Reidy-Lagunes outlines the current state of treatments for pancreatic neuroendocrine tumors (PNETs).
AVENGER 500 Clinical Trial Shows No Overall Survival Benefit
Data from the AVENGER 500 clinical trial explains why the trial’s goal was not met. A new trial with a different approach has launched.
Can SBRT Become More Effective?
Radiation oncologist Dr. Todd Aguilera is looking for ways to make SBRT a more effective treatment for pancreatic cancer.
Potential Therapy Takes a Two-Prong Attack on Pancreatic Cancer
With a focus on targeting cell metabolism, Dr. Anup Kasi leads a clinical trial of a new agent in combination with gemcitabine.
More Research Needed For Neuropathy
Dr. Allyson Ocean discusses the use of glutamine to ease the neuropathy caused by chemotherapy drugs for pancreatic cancer.
Dousing Out-of-Control KRAS Signaling in Pancreatic Cancer
Rene Bernards and his team are targeting the signaling pathway of the KRAS mutation, which occurs in almost all pancreatic cancers.
Multicenter Trial Focuses on Neoadjuvant Treatment for Borderline Resectable and Locally Advanced Disease
Dr. David Ryan outlines a new trial for pre-surgical pancreatic cancer treatment combining a blood pressure drug, immunotherapy, standard care and SBRT.
Targeted Therapy for Pancreatic Cancer
Dr. Margaret Tempero outlines the work being done in the area of targeted therapy for pancreatic cancer, specifically the testing of ibrutinib.